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Abstract  Heart  failure  (HF)  with  reduced  ejection  fraction  (HFrEF)  is  associated  with  high  rates
of hospitalization  and  death.  It  also  has  a  negative  impact  on  patients’  functional  capacity  and
quality of  life,  as  well  as  on  healthcare  costs.  In  recent  years,  new  HFrEF  prognosis-modifying
drugs have  emerged,  leading  to  intense  debate  within  the  international  scientific  community
toward a  paradigm  shift  for  the  management  of  HFrEF.  In  this  article,  we  report  the  contribution
of a  Portuguese  HF  expert  panel  to  the  ongoing  debate.
Based on  the  most  recently  published  clinical  evidence,  and  the  panel  members’  clinical
judgment,  three  key  principles  are  highlighted:  (i)  sacubitril/valsartan  should  be  preferred  as
first-line therapy  for  HFrEF,  instead  of  an  angiotensin-converting  enzyme  inhibitor  or  angiotensinur  foundation  HFrEF  drugs  are  the  angiotensin  receptor/neprilysin
blocking  agents,  mineralocorticoid  receptor  antagonists,  andoptimization;
Sacubitril/valsartan;
receptor blocker;  (ii)  the  fo
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sodium-glucose  co-transporter  2  inhibitors,  regardless  of  the  presence  of  type-2  diabetes  mel-
litus; (iii)  these  four  HFrEF  drug  classes  should  be  introduced  over  a  short-term  period  of  four
to six  weeks,  guided  by  a  safety  protocol,  followed  by  a  dose  up-titration  period  of  8  weeks.
© 2021  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an
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Otimização  do  tratamento  da  insuficiência  cardíaca  com  fração  de  ejeção  reduzida
com  fármacos  modificadores  de  prognóstico:  um  documento  de  consenso  de  2021  por
especialistas  em  insuficiência  cardíaca
Resumo  A  insuficiência  cardíaca  (IC)  com  fração  de  ejeção  reduzida  (ICFEr)  está  associada
a níveis  elevados  de  hospitalização  e  mortalidade.  A  ICFEr  também  tem  um  impacto  negativo
na capacidade  funcional  e  na  qualidade  de  vida  dos  doentes,  bem  como  na  despesa  em  saúde.
Nos últimos  anos,  surgiram  novos  medicamentos  modificadores  do  prognóstico  da  ICFEr,  origi-
nando um  intenso  debate  na  comunidade  científica  internacional  em  relação  a  uma  mudança
de paradigma  para  o  tratamento  da  ICFEr.  Neste  artigo,  relatamos  a  contribuição  de  um  painel
de especialistas  portugueses  em  IC  para  o  debate  em  curso.
Com  base  na  evidência  clínica  publicada  mais  recentemente  e  no  julgamento  clínico  dos  mem-
bros do  painel,  três  princípios-chave  são  destacados:  (i)  sacubitril/valsartan  deve  ser  preferido
como terapia  de  primeira  linha  para  a  ICFEr,  em  vez  de  um  inibidor  da  enzima  de  conversão
da angiotensina  ou  um  bloqueador  do  recetor  da  angiotensina;  (ii)  os  quatro  medicamentos
básicos para  a  ICFEr  são  o  inibidor  do  recetor  da  angiotensina  e  da  neprilisina,  os  agentes  blo-
queadores beta-adrenérgicos,  os  antagonistas  do  recetor  mineralocorticoide  e  os  inibidores  do
cotransportador  sódio-glucose  2,  independentemente  da  presença  de  diabetes  mellitus  tipo  2;
(iii) essas  quatro  classes  de  medicamentos  para  a  ICFEr  devem  ser  rapidamente  introduzidas
num período  curto  de  4-6  semanas,  seguindo  um  protocolo  de  segurança,  e  depois  tituladas
durante as  oito  semanas  seguintes.
© 2021  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é  um




































eart  failure  (HF)  with  reduced  ejection  fraction  (HFrEF)
s  a  fatal  condition.1 In  the  late  nineteen-eighties,  75%
f  HFrEF  patients  not  receiving  disease-modifying  ther-
py  would  not  survive  beyond  5  years  after  the  first
ymptoms.1 Additionally,  HF  is  a  major  cause  of  hospi-
alizations  and  has  a  strong  negative  impact  on  patients’
ymptoms,  functional  capacity  and  quality  of  life,  as  well
s  on  health  care  costs.2 Hospitalizations  are  the  main
river  of  HF-associated  costs3 and  are  primarily  caused  by
ongestion.4
During  the  nineteen-sixties,  thiazides5 and  loop-
iuretics6,7 were  introduced  to  control  congestion.  By  the
nd  of  the  nineteen-eighties,  vasodilators1 and  angiotensin-
onverting  enzyme  inhibitors  (ACEIs)8 had  been  proven
apable  of  reducing  HFrEF-related  mortality.  This  was  fol-
owed  by  an  intense  clinical  development  program,  resulting
n  the  emergence  of  angiotensin  receptor  blockers  (ARBs),9
eta  blockers  (BBs),10 mineralocorticoid  receptor  antago-
ists  (MRAs),11 angiotensin  receptor/neprilysin  inhibitors
ARNIs)12 and  sodium--glucose  cotransporter-2  inhibitors
SGLT2is),13,14 providing  further  significant  reductions  in
FrEF-related  morbidity  and  mortality.
3
2
Although  exciting,  the  present  HFrEF  therapeutic  sce-
ario  has  a  complex  decision  tree  in  terms  of  which  drugs  to
se  first,  in  which  patients,  in  what  sequence  to  introduce
he  subsequent  drugs,  how  fast  to  initiate  and  titrate  them,
nd  which  safety  monitoring  protocol  to  use  to  avoid  the
ost  frequent  serious  side  effects.  A  panel  of  six  Portuguese
F  experts  convened  to  address  these  issues,  based  on  the
ost  recently  published  clinical  evidence  and  on  their  own
linical  judgment.  This  position  paper  contains  three  central
essages:
.  Sacubitril/valsartan  (an  ARNI)  should  be  used  instead  of
an  ACEI  or  an  ARB,  as  the  preferential  first-line  therapy
for  HFrEF,15,16 unless  it  is  not  accessible  or  is  not  tolerated
by  the  patient;
.  The  four  foundational  HFrEF  drugs  are  ARNI  (substituted
by  ACEI  or  ARB  in  patients  with  intolerance  to  ARNI),  BB,
MRA,  and  SGLT2i  regardless  of  the  presence  of  type-2
diabetes  mellitus  (T2D).17.  These  four  drug  classes  should  be  introduced  at  a  low
dose,  over  a  short-term  period  of  four  to  six  weeks,  fol-
lowed  by  dose  up-titration  at  a  slower  pace  over  the
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eart failure with reduced ejection fraction
harmacological strategies in an ambulatory
etting
n  the  pathophysiology  of  HF,  there  is  an  important  sequence
f  events:  (i)  the  initial  aggression  that  causes  left  ventric-
lar  (LV)  dysfunction;  (ii)  neuro-hormonal  (NH)  activation;
iii)  LV  volume/pressure  overload  and  remodeling;  and  (iv)
urther  LV  dysfunction  and  NH  activation,  in  a  vicious  circle
f  inexorable  HF  worsening  --‘the  cardiomyopathy  of  over-
oad’  --  responsible  for  the  HF  poor  prognosis.19 Hence  the
hree  central  pharmacological  strategies  in  HFrEF  therapy
re:  congestion  control,  HR  control,  and  reducing  morbidity
nd  mortality  (see  Figure  1).20
ongestion  control
iuretics  are  recommended  to  reduce  the  signs  and  symp-
oms  of  congestion,  but  their  effects  on  mortality  and
orbidity  have  not  been  studied  in  randomized  clinical
rials  (RCTs).  A  meta-analysis  published  in  2020  showed
n  association  between  loop  diuretics  and  increased  HF-
ospitalizations  and  all-cause  mortality,21 particularly  when
igh  diuretic  doses  were  used.  The  authors  suggested  that
rospective  randomized  studies  could  clarify  whether  this
ssociation  is  due  to  reverse  causality.21 Diuretics  ther-
py  aims  to  achieve  euvolemia  with  the  minimal  effective
ose,  as  they  stimulate  the  renin-angiotensin-aldosterone
ystem  (RAAS).20,22 However,  because  they  reduce  LV  end-
iastolic  pressure,  diuretics  may  also  reduce  cytoskeletal
timulation,23 which  could  have  a  positive  effect  on  HF
hysiopathology,24 resulting  in  an  improvement  in  HF
rognosis.25 The  dose  of  diuretics  needs  to  be  adjusted
ccording  to  the  patient’s  condition  over  time.20,22
eart  rate  control
drenergic  stimulation  in  HF  increases  the  heart  rate  (HR).26
his  is  common  in  HFrEF  and  is  associated  with  poor
utcomes.27,28 When  the  patient  has  left  ventricular  ejec-
ion  fraction  (LVEF)  ≤35%,  is  symptomatic,  and  is  in  sinus
hythm  with  resting  HR  ≥70  beats/min,  despite  maximum
olerated  dose  of  a  BB  and  under  an  ACEI  (or  ARB)  and  an
RA,  sinus  node  If-channel  inhibition  with  ivabradine  should
e  considered.20 The  use  of  ivabradine  is  associated  with  a
educed  risk  of  HF  hospitalization  or  cardiovascular  death.29
he  optimal  resting  ventricular  rate  in  patients  with  atrial
brillation  (AF)  and  HF  is  still  a  matter  of  debate,  but  it  is
elieved  to  be  in  the  range  of  60--100  bpm.20 Ivabradine  has
o  place  in  AF  HR-control  as  its  effects  are  exerted  by  acting
n  the  sinus  node.30
educing  morbidity  and  mortality
fter  the  late  nineteen-eighties,  ACEIs,31 followed  by
Bs10 and  MRAs,11 emerged  as  central  players  in  HFrEF
rognosis-modifying  therapy.  Since  2014,  two  new  drug
lasses  have  joined  this  group:  sacubitril-valsartan12 and  two
GLT2i,  empagliflozin  and  dapagliflozin.13 More  recently,
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ew  players  have  been  added  to  the  HFrEF  treatment
ortfolio:  vericiguat,32 omecamtiv  mecarbil,33 and  intra-
enous  ferric  carboxymaltose.34 ACEIs,  ARBs,  MRAs  and  ARNI
re  collectively  designated  as  renin-angiotensin-aldosterone
ystem  inhibitors  (RAASi).35 RAASi  may  induce  hyperkalemia,
requently  leading  to  RAASi  down  titration/withholding
hich,  in  turn,  is  associated  with  a  worsening  prognosis.36
ew  potassium-binders  (patiromer  and  sodium  zirconium
yclosilicate)  allow  serum  K  to  be  maintained  within  normal
evels,  enabling  RAASi  therapy.37 Additionally,  in  patients
nder  MRAs,  it  has  been  shown  that  SGLT2i  reduce  the  occur-
ence  of  moderate  to  severe  hyperkalemia.38,39
014,  a paradigm  shift:  angiotensin  receptor
eprilysin  inhibitor  instead  of
ngiotensin-converting  enzyme  inhibitor  as  a
rst-line heart  failure  with  reduced  ejection
raction  therapy
n  2014,  the  PARADIGM-HF12 trial  demonstrated  that  in
atients  with  HFrEF,  sacubitril/valsartan  versus  enalapril
educed  the  risk  of  HF  hospitalization/cardiovascular  mor-
ality,  sudden  cardiac  death,  death  due  to  progressive  HF
nd  total  mortality.12 It  has  also  been  shown  that  sacubi-
ril/valsartan  reduces  the  rate  of  renal  function  decline  in
FrEF  when  compared  with  enalapril.40 Sacubitril/valsartan
as  also  superior  to  enalapril  in  terms  of  symptom  improve-
ent,  functional  capacity  and  quality  of  life.12 Both  drugs
howed  a  similar  safety  profile.12
The  positive  impact  of  sacubitril/valsartan  on  sudden
ardiac  death  (SCD)  in  HFrEF  patients  should  be  highlighted
ecause  in  the  SOLVD  trial,  it  was  shown  that  ACEIs  do  not
revent  SCD  in  this  population.31 This  is  particularly  relevant
iven  that  50%  of  HF  patients  are  New  York  Heart  Associa-
ion  (NYHA)  class  II.41,42 NYHA  class  II  patient  mortality  at
0  months  after  diagnosis  ranges  from  7%  to  15%43 with  64%
f  these  patients  dying  suddenly.42,44 This  is  contrary  to  the
ommon  belief  that  NYHA  class  II  represents  a  stable  condi-
ion.  Of  note,  the  superiority  of  sacubitril/valsartan  over
nalapril  regarding  SCD  achieved  statistical  significance  as
arly  as  one  month  after  the  start  of  therapy.45
In  patients  hospitalized  due  to  decompensated  chronic
F  or  new  onset  HF,  with/without  previous  exposure
o  ACEI/ARB,  the  safety  of  initiating  sacubitril-valsartan,
fter  hemodynamic  stabilization,  was  demonstrated  in  the
IONEER-HF40 and  TRANSITION46 studies.
Based  on  all  the  above  clinical  evidence,  the  American
ollege  of  Cardiology  (ACC)47 and  The  National  Institute  for
ealth  and  Care  Excellence  (NICE)48 now  recommend  sacu-
itril/valsartan  as  a  preferred  first-line  treatment  instead
f  an  ACEI/ARB.
019-2020:  ‘The  new  kids  on  the  block’
he  DAPA-HF13 study  in  2019  and  EMPEROR-reduced14 study
n  2020,  showed  that  sodium-glucose  co-transporter  2
nhibitors  (SGLT2i)  (dapagliflozin  and  empagliflozin  respec-
ively),  combined  with  recommended  HFrEF  therapy  further
educed  the  risk  of  HF-hospitalizations13,14 and  cardiovas-
ular  mortality,13 regardless  of  the  type  2  diabetes  (T2D).
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Figure  1  Central  Figure.  The  pathophysiology  of  heart  failure  with  reduced  ejection  fraction  (HFrEF)  and  the  four  foundational
HFrEF prognosis-modifying  drugs:  angiotensin  receptor/neprilysin  inhibitor  (ARNI),  beta-adrenergic  blocking  agents  (BBs),  min-













































































ralocorticoid  receptor  antagonists  (MRAs),  and  sodium-glucos
ecognized mechanisms;  the  dashed  arrows  represent  possible  
he  apparent  divergence  between  these  two  studies  in  rela-
ion  to  the  effect  on  cardiovascular  mortality,  in  favor  of
apagliflozin,  has  been  interpreted  by  HF  experts  as  being
ue  to  differences  in  study  design,  such  as  patient  charac-
eristics,  sample  size  and  follow-up  times.49
In  the  DAPA-HF  study,  it  was  demonstrated  that
apagliflozin  has  a  very  early  positive  impact  on  worsening
F/cardiovascular  death,  which  reached  statistical  signifi-
ance  as  early  as  28  days  after  randomization.50 Similarly,
n  the  EMPEROR-Reduced  study,  the  benefit  of  empagliflozin
n  reducing  the  risk  of  worsening  HF  events  was  found  to
e  statistically  significant  at  12  days  after  randomization.51
oreover,  both  studies  have  also  shown  a  clear  benefit  in
erms  of  cardiovascular  and  renal  protection.13,14
Based  on  this  body  of  evidence  SGLT2i  (dapagliflozin  and
mpagliflozin)  are  presently  considered  the  fourth  pillar  of
FrEF  prognosis-modifying  therapy,  regardless  of  the  pres-
nce  of  diabetes,  and  on  top  of  the  triple  neurohormonal
odulation/blockade  (ACEI/ARB/ARNI+BB+MRA).17,47
The  SOLOIST-WHF  study  showed  a  positive  prognos-
ic  impact  of  sotagliflozin  (a  SGTL2  and  SGLT1  inhibitor)
ompared  to  placebo  in  patients  with  T2D  and  a  recent  wors-
ning  HF-event.52 Sotagliflozin,  initiated  before  or  shortly
fter  hospital  discharge,  has  been  shown  to  reduce  cardio-
ascular  mortality,  HF-hospitalizations  and  urgent  hospital
isits.52
he  ‘fantastic  four’
he  current  profusion  of  HFrEF  disease-modifying  drugs  calls
or  a  strategy  on  how  to  optimize  their  coordinated  use  in
linical  practice.  By  the  end  of  2020,  John  McMurray  and
ilton  Packer  had  challenged  the  classical  drug  implemen-
ation  strategy  based  on  the  principle  of  introducing  and
ull-titrating  one  single  prognosis-modifying  drug  at  a  time
efore  adding  another  prognosis-modifying  drug.18 These
uthors  highlighted  the  four  foundation  drug  classes  to  be
ntroduced  as  soon  as  possible  in  the  HFrEF  therapeutic  reg-
men:  ARNI,  BB,  MRA  and  SGLT2i.18 Johann  Bauersachs,  in
n  allegory  to  the  Marvel  Comics’  superhero-team  ‘The  fan-
astic  four’  used  this  term  to  designate  these  four  HFrEF
isease-modifying  drug  classes.53 Comprehensive  HFrEF
isease-modifying  therapy  (ARNI+BB+MRA+SGLT2i)  is  clearly






transporter  2  inhibitors  (SGLT2i).  The  filled  arrows  represent
anisms.
f  reducing  cardiovascular  death  or  HF-hospitalizations
OR=0.38;  95%  CI  0.30--0.47).54,55 These  four  classes  of  drugs
hould,  therefore,  be  considered  the  new  standard  of  HFrEF
herapy.53
trategies for the implementation of HFrEF
rognosis-modifying drugs after 2020
he  classical  view:  Titrate  first,  add  later
he  classical  HFrEF  therapeutic  strategy  mimics  the  histori-
al  sequence  in  which  disease-modifying  drugs  were  tested
n  RCTs  from  the  late  eighties  onward.20 These  foundational
CTs  thus  constituted  the  backbone  of  this  evidence-based
trategy  which,  in  turn,  emulated  the  clinical  protocols  used
n  the  research  and  development  programs.  Furthermore,
his  approach  incorporated  evidence  showing  that  disease-
odifying  drugs  are  more  effective  at  high-doses  than  at
ow  doses.20 Therefore,  therapy  initiation  with  an  ACEI/ARB
lus  a  BB  at  low  doses  was  recommended,  followed  by  up-
itration  to  maximal  target  doses.20 For  patients  remaining
ymptomatic  and  with  LVEF  ≤35%  despite  this  therapeutic
egimen,  a second  step  followed,  with  the  addition  of  a  MRA
t  low  dose,  subsequently  up-titrated  to  maximum  doses.20
inally,  in  patients  still  symptomatic  and  with  LVEF  ≤35%
nder  ACEI/ARB+BB+MRA  therapy,  replacement  of  ACEI/ARB
y  an  ARNI,  titrated  to  maximal  doses,  was  recommended
y  the  2016  European  Society  of  Cardiology  Heart  Failure
uidelines.20
However,  the  above  strategy  may  no  longer  be  appro-
riate,  as  the  drugs  that  were  first  discovered  are  not
ecessarily  the  most  effective  ones.18 Additionally,  this
lassical  strategy  results  in  a  lengthy  period  for  the  full
mplementation  of  disease-modifying  drugs,  often  taking
everal  (typically  six  or  more)  months  to  be  completed.56
his  is  relevant  because,  as  previously  mentioned,  time  does
atter,  as  the  impact  on  prognosis  of  disease-modifying
rugs  reaches  statistical  significance  in  a  short-term  period
f  a  few  weeks  --  so  early  as  two  weeks,  as  observed  for
he  empagliflozin  induced  benefit.11,12,49,54,57 Furthermore,
n  RCTs  as  well  as  in  everyday  clinical  practice,  a  high  per-
entage  of  patients  cannot  reach  the  optimal  drug  target
oses  due  to  the  occurrence  of  side  effects  such  as  hypoten-
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he  accelerated  pathway:  Add  first,  titrate  later
t  has  recently  been  shown  that  the  initial  combination
f  two  disease-modifying  drugs  at  low  dose  generates
etter  outcomes  than  full  up-titration  of  only  one  disease-
odifying  drug.18,58 This  calls  for  the  combination  of  several
isease-modifying  drugs  at  low  dose  at  the  start  of  HF
herapy.18 Since  much  of  the  clinical  benefit  of  these  drugs
s  observed  within  a  few  weeks,11,12,49,54,57 some  authors  pro-
ose  that  the  four  classes  of  HF  disease-modifying  drugs
hould  be  initiated  during  a  short-term  period  of  4  weeks.18
cMurray  and  Packer  suggest  initiating  therapy  with  the
ombination  of  a  BB  and  a  SGLT2i,  followed  within  one  to
wo  weeks  by  the  addition  of  sacubitril/valsartan,  and  after
 further  one  to  two  weeks,  the  addition  of  a  MRA.18 After
hat,  the  dose  up-titration  of  the  drugs  should  follow  at  a
lower  pace.18
The  strategy  of  McMurray  and  Packer  has  a  strong  ratio-
ale,  as  it  targets  several  different  pathophysiological  steps
n  a  fast  sequence,  although  there  is  no  randomized  clinical
rial  to  support  this.  In  addition,  since  their  strategy  calls
or  starting  all  four  disease-modifying  drug  classes  within  4
eeks,  one  could  argue  that  the  suggested  specific  sequence
f  drug  initiation  may  not  be  determinant  in  clinical  prac-
ice.
he  2021  Update  to  the  2017  American  College  of
ardiology Expert  Consensus  for  Heart  Failure
reatment
he  2021  update  to  the  2017  ACC  Expert  Consensus  Deci-
ion  Pathway  for  Optimization  of  Heart  Failure  Treatment47
roposes  an  algorithm  for  HFrEF  stage  C  therapy,  start-
ng  with  an  ARNI  (preferably)  or  an  ACEI/ARB  plus  a
B,  which  should  be  up-titrated  every  two  weeks  to  the
aximum  tolerated  or  target  doses.47 An  MRA  and/or
GLT2i  may  be  added,  as  well  as  ivabradine,  diuret-
cs  and/or  a  hydralazine+isosorbide  dinitrate  combination,
ccording  to  the  patient’s  condition/phenotype.47 This  ACC
xpert  Consensus  suggests  considering  dose  up-titration
very  two  weeks  in  the  case  of  MRA,  ivabradine,  and/or
ydralazine+isosorbide  dinitrate  until  the  maximum  toler-
ted  or  target  dose  is  achieved.47
he  2021  Update  to  the  Canadian  Cardiovascular
ociety/Canadian  Heart  Failure  Society  Heart
ailure Guidelines
he  2021  update  to  the  Canadian  Cardiovascular  Soci-
ty/Canadian  Heart  Failure  Society  (CCS/CHFS)  heart  failure
uidelines  recognizes  the  combination  of  the  four  founda-
ional  HF  disease-modifying  drug  classes  as  the  standard
herapy  for  the  majority  of  HFrEF  patients.59 This  includes
n  ARNI  (preferably  to  an  ACEi/ARB),  plus  a  BB,  plus  a  MRA,
lus  a  SGLT2i.59 Depending  on  the  patient’s  clinical  char-
cteristics,  other  therapies  may  also  be  recommended,  in
rder  to  improve  prognosis,  symptoms,  congestion,  or  HR
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he  2021  European  Society  of  Cardiology/Heart
ailure  Association  Heart  Failure  Guidelines
review
n  a  joint  ESC/Heart  Failure  Association  (HFA)  Session  at
SC  Heart  Failure  2021  Congress  (June  29,  2021),  Theresa
cDonagh  and  Marco  Metra  addressed  the  upcoming  2021
eart  Failure  ESC  Guidelines  and  the  expected  update  to  the
FrEF  therapy  algorithm.  ACEI  is  recommended  for  patients
ith  HFrEF  to  reduce  the  risk  of  HF  hospitalizations  and
eath  (class  I indication,  level  of  evidence  (LOE)  A).  Sacubi-
ril/valsartan  is  recommended  as  a  replacement  for  an  ACEI
n  patients  with  HFrEF  to  reduce  the  risk  of  HF  hospitaliza-
ion  and  death  (indication  class  I,  LOE  B).  Concomitantly,
apid  initiation  of  a BB,  plus  an  MRA,  plus  a  SGLT2i  is  also
ecommended  as  a  first  step  ‘to  reduce  mortality  for  all
atients’.  Additionally,  a  personalized  approach  is  suggested
to  reduce  hospitalization/mortality  for  selected  patients’,
ncluding  diuretics  and  other  drug  interventions  according
o  the  patient’s  profile.60
he  Portuguese  Heart  Failure  Expert  Panel
his  proposal  of  the  Portuguese  HF  Expert  Panel  for  a
FrEF  drug  initiation  algorithm  builds  on  the  McMurray
nd  Packer’s  paper,18 the  2021  update  to  the  2017  ACC
F  Expert  Consensus,47 the  2021  update  to  the  CCS/CHFS
eart  Failure  Guidelines,  and  the  2021  ESC/HFA  Heart
ailure  Guidelines  preview.  In  addition,  this  proposal  dis-
inguishes  different  strategies  for  diabetic  and  non-diabetic
atients  and  includes  a  safety  monitoring  protocol  to  ensure
apid  treatment  initiation  and  up-titration.  Finally,  this
roposal  recommends  that  HFrEF  treatment  optimization
hould  be  individualized  according  to  the  patient’s  condition
nd  phenotype.59 This  algorithm  aims  to  provide  practical
uidance  on  how  to  proceed  in  regard  to  HFrEF  prognosis-
odifying  drug  optimization  in  everyday  clinical  practice.
The  following  key  evidence-based  principles  were  con-
idered:
 in  HFrEF  patients,  sacubitril/valsartan  is  clearly  superior
to  ACEIs  in  terms  of  prognostic  impact12;
 dapagliflozin  or  empagliflozin,  on  top  of  optimized  HFrEF
therapy  (ACEI/ARB/ARNI+BB+MRA)  further  reduce  the  risk
of  HF-hospitalisations13,14 and  cardiovascular  mortality,
regardless  of  the  presence  of  diabetes.13
Thus,  the  core  of  HFrEF  disease-modifying  therapy
ncludes  four  drug  classes:  ARNI,  BB,  MRA  and  SGLT2i.
The  panel  also  considered  the  following  evidence-based
bservations:
 Time  matters  when  initiating  HFrEF  disease-modifying
therapy,  since  ARNI,12 BBs,57 MRAs,11,61 and  SGLT2i13,14 all
show  a  positive  prognostic  impact  as  early  as  a  few  weeks
after  the  initiation  of  therapy;
 The  combined  action  of  two  disease-modifying  drugs  at
low  doses  shows  a  higher  prognostic  impact  than  a  high
dose  of  a  single  drug18,58;
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nitiation of  the  four  foundational  drugs.
 In  HFrEF  patients,  with  or  without  diabetes,  SGLT2i,  on
top  of  optimized  HFrEF  therapy,  are  associated  with  a
better  prognosis  compared  to  placebo13,14;
 Although  evidence  for  SGLT2i  prognostic  gains  in  HFrEF
results  from  studies  where  these  drugs  were  used  on
top  of  HF  optimized  therapy,  the  current  guidelines  of
the  American  Diabetes  Association  recommend  SGLT2i  for
T2D  patients  with  HF,  particularly  those  with  LVEF  <45%,
as  part  of  the  glucose-lowering  regimen,  regardless  of
hemoglobin  A1c  level,  and  in  addition  to  metformin  and
comprehensive  lifestyle  intervention.62
In  summary,  we  recommend  that  the  traditional  start  low
nd  go  slow  HFrEF  therapy  initiation  aphorism20 be  changed
o  a  start  low  and  add  fast  strategy,  which  means  start-
ng  the  four  foundational  HF  disease-modifying  drug  classes
ithin  a  four  to  six  week  interval.  This  initial  effort  should
e  implemented  at  low  drug  doses.  Dose  up-titration  follows
hereafter,  as  quickly  as  possible,  guided  by  an  effective
afety  monitoring  protocol.
Considering  the  above,  the  Portuguese  HF  Expert  Panel
ecommends  the  following  protocol  for  the  drug  initia-
ion,  drug  up-titration  and  treatment  monitoring  of  HFrEF
atients.
rug  initiation  phase
or  HFrEF  patients  with  T2D,  a  2-step  disease-modifying
rug  initiation  strategy  is  recommended  --  see  Figure  2:
 Step  1:  Initiation  of  SGLT2i+ARNI  (at  an  intermediate/low
dose)+BB  (at  a  low  dose);
 Step  2:  Addition  of  a  MRA  (at  a  low  dose)  4  to  6  weeks
after  step  1.
Step  1  is  in  line  with  the  2021  guidelines  of  the  American
iabetes  Association  which,  as  mentioned  above,  recom-
ends  timely  SGLT2i  therapy  for  T2D  with  HF.62
For  HFrEF  patients  with  no  T2D,  a  three-step  disease-
odifying  drug  initiation  with  a  SGLT2i  on  top  of  ARNI,  BB
nd  MRA,  is  recommended  --  see  Figure  3:
6
 Step  1:  Initiation  of  ARNI  (at  an  intermediate/low
dose)+BB  (at  a low  dose);
 Step  2:  Addition  of  a  MRA  (at  a  low  dose)  2  to  3  weeks
after  step  1;
 step  3:  Addition  of  a  SGLT2i  2  to  3  weeks  after  step  2.
The  four  disease-modifying  drug  classes  should  be  initi-
ted  within  4-6  weeks.  In  patients  intolerant  to  ARNI,  an
CEI  or  an  ARB  should  be  considered  as  an  alternative.
rug  up-titration  phase
n  HF,  SGLT2i  up-titration  is  not  required.47 For  the  other
hree  disease-modifying  drug  classes,  we  recommend  up-
itrating  one  drug  at  a  time,  to  minimize  the  occurrence  of
omplications.  Up-titration  steps  for  each  drug  should  occur
very  two  weeks  at  an  in-person  visit.  Considering  on  aver-
ge,  one  up-titrating  step  for  ARNI,  two  for  BBs  and  one
or  MRAs,  most  HFrEF  patients  may  initiate  and  fully  up-
itrate  all  four  disease-modifying  drugs  within  a  12  to  14
eek  period.
onitoring  protocol
e  suggest  a  monitoring  protocol  including  in-person  and
emote  appointments,63 to  guarantee  patient  safety  and
llow  a  more  agile  therapy  optimization.
During  the  drug  initiation  phase,  we  recommend  the  fol-
owing:
 In  step  one,  the  in-person  visit  (day-1)  Step  one  assigned
drugs  should  be  initiated  and  the  patient  should  be
instructed  to  record  their  daily  symptoms,  weight,  HR  and
blood  pressure.  On  day  six,  serum  creatinine  and  potas-
sium  levels  should  be  measured.  On  day  seven,  an  online
visit  should  be  performed  to  check  the  above  data  and  to
modify  the  therapy,  if  needed  for  safety  reasons.63
 The  step  two  visit  should  be  an  in-person  appointment,
two  to  three  weeks  after  the  step  one  visit.  The  step  two
assigned  drug  should  be  initiated.  The  same  methodol-
ogy  as  described  above  for  the  step  one  visit  should  be
followed.
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igure  3  Treatment  algorithm  for  H  heart  failure  with  reduc
or the  initiation  of  the  four  foundational  drugs.
 For  non-diabetic  HF  patients,  a  step  three  in-person  visit
should  take  place  two  to  three  weeks  after  step  two  visit.
The  step  three  assigned  drug  should  be  initiated.  The
same  methodology  as  described  above  for  the  step  one
visit  should  be  followed.
During  the  drug  up-titration  phase,  we  recommend  that
ach  up-titration  step  occur  at  a  two-week  interval  at  an
n-person  visit.  Patients  should  be  instructed  to  record  their
aily  symptoms,  weight,  HR  and  blood  pressure.  On  day  6
fter  each  up-titration  step,  measurement  of  serum  crea-
inine  and  potassium  levels  should  be  performed.  On  day
even  after  each  up-titration  step,  an  online  visit  should  be
erformed  to  check  the  above  data  and  modify  the  therapy,
f  needed  for  safety  reasons.
Telemonitoring  may  be  useful  during  both  initiation  and
p-titration  phases  especially  in  more  unstable  patients.63
In  summary,  the  following  three-step  aphorism  condenses
he  central  messages  of  the  Portuguese  Heart  Failure  Expert
anel:
 start  low  (and  early)  and  add  fast;
 titrate  later  (to  maximally  tolerated  doses);
 tailor  according  to  the  patient’s  profile  (blood  pressure,
renal  function,  serum  potassium  level,  HR  and  the  pres-
ence  of  atrial  fibrillation  and/or  other  co-morbidities).
onclusion
hese  recommendations  of  the  Portuguese  HF  Expert
anel  add  to  the  ongoing  international  debate  toward
 HFrEF  management  paradigm  shift.  Our  recommenda-
ions  build  on  the  central  notion  that  presently,  the  core
f  HFrEF  disease-modifying  therapy  includes  four  first-
ine  drug  classes:  sacubitril/valsartan,  beta-blockers,  MRAs
nd  sodium-glucose  co-transporter-2  inhibitors.  Sacubi-
ril/valsartan,  should  be  preferred  as  a  first-line  HFrEF
herapy,  instead  of  an  ACEI  or  an  ARB.  In  addition,  our  rec-
mmendations  differentiate  the  implementation  sequence






jection  fraction  non-diabetic  patients:  A  three-step  sequence
iabetic  status  and  include  a  safety  monitoring  protocol  to
nsure  rapid  treatment  initiation  and  up-titration.
Another  important  concept  is  that  time  is  of  essence
hen  targeting  better  outcomes  for  HFrEF  patients.  Thus,
deally,  all  four  drug  classes  should  be  introduced  at  a  low
ose  during  a  four  to  six  week  period  and  up-titrated  there-
fter  during  a  period  of  8  weeks.  Following  this  rationale,  we
uggest  a  safety  monitoring  protocol,  including  face-to-face
nd  remote  evaluations  to  facilitate  rapid  HFrEF  treatment
ptimization.63 Telemonitoring  should  be  implemented  in
ore  unstable  patients.63
This  set  of  recommendations  by  the  Portuguese  HF  Expert
anel  should  not  be  regarded  as  a  rigid  protocol,  but  rather,
s  guidance,  as  HFrEF  treatment  optimization  should  always
e  adapted  to  the  specific  circumstances  of  the  individual
atient.
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